Skip to main content
SpringerLink
Log in

Penetration of topically applied tacrolimus into the aqueous humor in Behçet’s disease

  • Original Article
  • Published:
Annals of Ophthalmology

Abstract

We investigated the concentration of tacrolimus in aqueous humor, and serum of patients with ocular Behçet’s disease after topical application in 11 patients. All received 1 drop of isotonic tacrolimus solution 0.3% every 6 hours for 3 days. The mean tacrolimus concentration in the aqueous and serum, as measured by microparticle enzyme immunoassay, were 12.49 and 0.76 ng/mL, respectively. Tacrolimus may be a promising treatment modality in anterior uveitis in Behçet’s disease by topical application.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kino T, Hatanaka H, Hashimoto H, et al. FK-506, a novel immunosuppresant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 1987; 40:1249–1255.

    PubMed  CAS  Google Scholar 

  2. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppresant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987;40:1256–1265.

    PubMed  CAS  Google Scholar 

  3. Sawada S, Suzuki G, Kawase Y, et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987;139:1797–1803.

    PubMed  CAS  Google Scholar 

  4. Whitcup SM, Pleyer U, Lai JC, et al. Topical liposome-encapsulated FK506 for the treatment of endotoxin-induced uveitis. Ocul Immunol Inflamm 1998;6:51–56.

    Article  PubMed  CAS  Google Scholar 

  5. Kawashima H, Fujino Y, Mochizuki M. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1988;29:1265–1271.

    PubMed  CAS  Google Scholar 

  6. Hikita N, Chan CC, Whitcup SM, et al. Effects of topical FK506 on endotoxin-induced uveitis (EIU) in the Lewis rat. Curr Eye Res 1995;14:209–214.

    PubMed  CAS  Google Scholar 

  7. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999;106:723–728.

    Article  PubMed  CAS  Google Scholar 

  8. Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocular Immunol and Inflamm 1998;6:101–109.

    Article  CAS  Google Scholar 

  9. Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK506 in refractory uveitis, including Behcet’s disease. Transplant Proc 1991;23:3343–3346.

    PubMed  CAS  Google Scholar 

  10. Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994;118:723–729.

    PubMed  CAS  Google Scholar 

  11. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporin for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977–983.

    Article  PubMed  CAS  Google Scholar 

  12. Pleyer U, Lutz S, Jusko WJ, et al. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci 1993;34:2737–2742.

    PubMed  CAS  Google Scholar 

  13. Mills RA, Jones DB, Winkler CR, et al. Topical FK-506 prevents experimental corneal allograft rejection. Cornea 1995; 14:157–160.

    Article  PubMed  CAS  Google Scholar 

  14. Okada K, Sakata H, Minamoto A, et al. Effect of FK506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. Ophthalmologica 1996;210: 175–179.

    Article  PubMed  CAS  Google Scholar 

  15. Hikita N, Lopez JS, Chan CC, Mochizuki M, et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci 1997;38:901–909.

    PubMed  CAS  Google Scholar 

  16. Fitzgerald P, Hadgraft J, Wilson CG. A gamma-scintigraphic evaluation of microparticulate ophthalmic delivery systems: liposomes and nanoparticles. Int J Pharm 1987;40:81–88.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ophthalmology Department, Ankara University Faculty of Medicine, Esat Caddes i 74/3 Küçükesat, 06660, Ankara, Turkey

    F. Nilüfer Yalçindaĝ MD, Figen Batioĝlu MD & Özden Özdemir MD

Authors
  1. F. Nilüfer Yalçindaĝ MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Figen Batioĝlu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Özden Özdemir MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Nilüfer Yalçindaĝ MD.

Additional information

The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer or provider of services discussed in this article. The authors also do not discuss the use of off-label products, which includes unlabeled, unapproved, or investigative products or devices.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yalçindaĝ, F.N., Batioĝlu, F. & Özdemir, Ö. Penetration of topically applied tacrolimus into the aqueous humor in Behçet’s disease. Ann Ophthalmol 39, 15–17 (2007). https://doi.org/10.1007/BF02697321

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02697321

Keywords

Search

Navigation